vTv Therapeutics Inc. (VTVT)
vTv Therapeutics Statistics
Share Statistics
vTv Therapeutics has 2.61M shares outstanding. The number of shares has increased by 7.37% in one year.
Shares Outstanding | 2.61M |
Shares Change (YoY) | 7.37% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | 4.23% |
Shares Floating | 1.48M |
Failed to Deliver (FTD) Shares | 272 |
FTD / Avg. Volume | 1.22% |
Short Selling Information
The latest short interest is 28.85K, so 1.1% of the outstanding shares have been sold short.
Short Interest | 28.85K |
Short % of Shares Out | 1.1% |
Short % of Float | 1.94% |
Short Ratio (days to cover) | 1.5 |
Valuation Ratios
The PE ratio is -4.32 and the forward PE ratio is -2.98. vTv Therapeutics's PEG ratio is 0.06.
PE Ratio | -4.32 |
Forward PE | -2.98 |
PS Ratio | 78.37 |
Forward PS | 282 |
PB Ratio | 6.53 |
P/FCF Ratio | -3.15 |
PEG Ratio | 0.06 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for vTv Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.34, with a Debt / Equity ratio of 0.01.
Current Ratio | 7.34 |
Quick Ratio | 7.34 |
Debt / Equity | 0.01 |
Debt / EBITDA | -0.01 |
Debt / FCF | -0.01 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $44.22K |
Profits Per Employee | $-802.7K |
Employee Count | 23 |
Asset Turnover | 0.03 |
Inventory Turnover | n/a |
Taxes
Income Tax | 100K |
Effective Tax Rate | -0.54% |
Stock Price Statistics
The stock price has increased by -34.13% in the last 52 weeks. The beta is 1.07, so vTv Therapeutics's price volatility has been higher than the market average.
Beta | 1.07 |
52-Week Price Change | -34.13% |
50-Day Moving Average | 17.35 |
200-Day Moving Average | 16.16 |
Relative Strength Index (RSI) | 50.68 |
Average Volume (20 Days) | 22.33K |
Income Statement
In the last 12 months, vTv Therapeutics had revenue of 1.02M and earned -18.46M in profits. Earnings per share was -3.2.
Revenue | 1.02M |
Gross Profit | 1.02M |
Operating Income | -24.18M |
Net Income | -18.46M |
EBITDA | -22.52M |
EBIT | -22.61M |
Earnings Per Share (EPS) | -3.2 |
Balance Sheet
The company has 36.75M in cash and 169K in debt, giving a net cash position of 36.58M.
Cash & Cash Equivalents | 36.75M |
Total Debt | 169K |
Net Cash | 36.58M |
Retained Earnings | -299.72M |
Total Assets | 38.27M |
Working Capital | 32.92M |
Cash Flow
In the last 12 months, operating cash flow was -25.31M and capital expenditures 0, giving a free cash flow of -25.31M.
Operating Cash Flow | -25.31M |
Capital Expenditures | 0 |
Free Cash Flow | -25.31M |
FCF Per Share | -4.39 |
Margins
Gross margin is 100%, with operating and profit margins of -2377.58% and -1815.34%.
Gross Margin | 100% |
Operating Margin | -2377.58% |
Pretax Margin | -1805.51% |
Profit Margin | -1815.34% |
EBITDA Margin | -2213.96% |
EBIT Margin | -2377.58% |
FCF Margin | -2488.4% |
Dividends & Yields
VTVT does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for VTVT is $35, which is 111.6% higher than the current price. The consensus rating is "Buy".
Price Target | $35 |
Price Target Difference | 111.6% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on Nov 21, 2023. It was a backward split with a ratio of 1:40.
Last Split Date | Nov 21, 2023 |
Split Type | backward |
Split Ratio | 1:40 |
Scores
Altman Z-Score | -10.7 |
Piotroski F-Score | 2 |